Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-7375 in Advanced KRAS G12D-Mutated Solid Tumors
NCT07020221Phase 2Recruiting
- Sponsor
- Verastem Oncology
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of GFH375 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (14 arms), sponsored by Verastem Oncology. Primary endpoints: Safety, tolerability, and adverse event profile up to 2.5 years, Maximum Tolerated Dose or Maximum Feasible Dose and 3 more. Started Jun 2025; status: recruiting.
02
Drugs
GFH375
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07020221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020221.